Skip to main navigation
Skip to search
Skip to main content
Bar-Ilan University Home
Help & FAQ
Link opens in a new tab
Search content at Bar-Ilan University
Home
Researchers
Organisations
Research output
Prizes
Student theses
Courses
Activities
Projects
Press/Media
Datasets
Equipment
Molecular targeted therapy of BRAF-mutant colorectal cancer
Michel Ducreux
, Ali Chamseddine
, Pierre Laurent-Puig
, Cristina Smolenschi
, Antoine Hollebecque
, Peggy Dartigues
, Emmanuelle Samallin
, Valérie Boige
, David Malka
, Maximiliano Gelli
Institut Gustave Roussy
Hôpital européen Georges Pompidou
Centre régional de lutte du cancer Val d'Aurelle
Research output
:
Contribution to journal
›
Review article
›
peer-review
91
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Molecular targeted therapy of BRAF-mutant colorectal cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
5-fluorouracil (5-FU)
33%
Bevacizumab
66%
BRAF Inhibitor (BRAFi)
100%
BRAF mutant
100%
BRAF mutation
33%
BRAF V600E mutation
33%
Cetuximab
33%
Chemotherapy
33%
Chemotherapy Combinations
33%
Colorectal Cancer
100%
Epidermal Growth Factor Receptor Inhibitors (EGFRI)
100%
Epidermal Growth Factor Receptor Signaling
33%
Feedback Activation
33%
First-line Chemotherapy
33%
Irinotecan
66%
MEK Inhibitor (MEKi)
33%
Melanoma
33%
Metastatic Colorectal Cancer (mCRC)
100%
Molecular Characterization
33%
Molecular Targeted Therapy
100%
Monotherapy
66%
Oxaliplatin
33%
Poor Prognosis
66%
Randomized Trial
33%
Second-line Treatment
66%
Therapeutic Targeting
33%
Treatment Lines
33%
Vemurafenib
33%
Medicine and Dentistry
Anti-Epidermal Growth Factor Receptor
66%
Bevacizumab
66%
Cetuximab
33%
Chemotherapy
33%
Colorectal Carcinoma
100%
Combination Chemotherapy
33%
Epidermal Growth Factor Receptor
66%
First-Line Chemotherapy
33%
Fluorouracil
33%
Hope
33%
Irinotecan
66%
MEK Inhibitor
33%
Melanoma
33%
Metastatic Colorectal Cancer
100%
Molecularly Targeted Therapy
100%
Monotherapy
66%
Oxaliplatin
33%
Post-Hoc Analysis
33%
Vemurafenib
33%
Pharmacology, Toxicology and Pharmaceutical Science
Bevacizumab
50%
Cetuximab
25%
Chemotherapy Regimens
50%
Colorectal Carcinoma
100%
Epidermal Growth Factor Receptor
100%
First-Line Chemotherapy
25%
Fluorouracil
25%
Irinotecan
50%
Melanoma
25%
Metastatic Colorectal Cancer
75%
Mitogen Activated Protein Kinase Kinase Inhibitor
25%
Monotherapy
50%
Oxaliplatin
25%
Vemurafenib
25%